89.07 USD
+4.98
5.92%
At close Feb 14, 4:00 PM EST
After hours
89.29
+0.22
0.25%
1 day
5.92%
5 days
0.78%
1 month
12.50%
3 months
19.27%
6 months
27.15%
Year to date
13.46%
1 year
-23.71%
5 years
25.49%
10 years
470.96%
 

About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Employees: 9,600

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

5% less call options, than puts

Call options by funds: $405M | Put options by funds: $424M

6% less repeat investments, than reductions

Existing positions increased: 325 | Existing positions reduced: 344

7.55% less ownership

Funds ownership: 96.97% [Q2] → 89.41% (-7.55%) [Q3]

12% less funds holding

Funds holding: 982 [Q2] → 869 (-113) [Q3]

36% less funds holding in top 10

Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]

45% less capital invested

Capital invested by funds: $43.7B [Q2] → $24B (-$19.7B) [Q3]

51% less first-time investments, than exits

New positions opened: 98 | Existing positions closed: 199

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$82
8%
downside
Avg. target
$98
10%
upside
High target
$115
29%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
Canaccord Genuity
William Plovanic
71% 1-year accuracy
35 / 49 met price target
16%upside
$103
Buy
Maintained
14 Feb 2025
Morgan Stanley
Patrick Wood
73% 1-year accuracy
8 / 11 met price target
8%downside
$82
Equal-Weight
Maintained
14 Feb 2025
Redburn Atlantic
Issie Kirby
25% 1-year accuracy
1 / 4 met price target
29%upside
$115
Buy
Upgraded
3 Feb 2025
Baird
Jeff Johnson
38% 1-year accuracy
5 / 13 met price target
17%upside
$104
Outperform
Upgraded
16 Jan 2025
Citigroup
Joanne Wuensch
66% 1-year accuracy
31 / 47 met price target
2%upside
$91
Buy
Maintained
11 Dec 2024

Financial journalist opinion

Based on 18 articles about DXCM published over the past 30 days

Positive
Benzinga
2 days ago
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
Positive
Benzinga
2 days ago
DexCom Analysts Increase Their Forecasts After Q4 Earnings
DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday.
DexCom Analysts Increase Their Forecasts After Q4 Earnings
Positive
Zacks Investment Research
2 days ago
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
Neutral
Seeking Alpha
2 days ago
DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Jake Leach - Chief Operating Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Robbie Marcus - J.P. Morgan Danielle Antalffy - UBS Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Steve Lichtman - Oppenheimer Issie Kirby - Redburn-Atlantic Michael Polark - Wolfe Research Patrick Wood - Morgan Stanley Sam Eiber - BTIG Mike Kratky - Leerink Operator Thank you for standing by.
DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
Positive
The Motley Fool
2 days ago
DexCom: Revenue Up, EPS Misses Mark
DexCom (DXCM 0.26%), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which reached $1.114 billion, slightly exceeding analysts' expectations of $1.112 billion.
DexCom: Revenue Up, EPS Misses Mark
Positive
Zacks Investment Research
2 days ago
Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings
The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings
Negative
Zacks Investment Research
2 days ago
DexCom (DXCM) Misses Q4 Earnings Estimates
DexCom (DXCM) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.50 per share a year ago.
DexCom (DXCM) Misses Q4 Earnings Estimates
Positive
Reuters
2 days ago
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
Negative
Investors Business Daily
3 days ago
Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations
Dexcom stock fell late Thursday after the company missed fourth-quarter profit expectations by a nickel per share. The post Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations appeared first on Investor's Business Daily.
Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations
Neutral
Business Wire
3 days ago
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results.
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Charts implemented using Lightweight Charts™